<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322608</url>
  </required_header>
  <id_info>
    <org_study_id>NPI-2358-100</org_study_id>
    <nct_id>NCT00322608</nct_id>
  </id_info>
  <brief_title>Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma</brief_title>
  <official_title>Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nereus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nereus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics&#xD;
      of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory&#xD;
      solid tumors or lymphoma. The formation of new blood vessels (angiogenesis) is an important&#xD;
      component of tumor growth and vascular disrupting agents are intended to target the&#xD;
      differences between these tumor blood vessels and the blood vessels in normal tissues.&#xD;
      NPI-2358 has also been seen to directly affect tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>continuously</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>continuously</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>continuously</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>continuously</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>continuously</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>continuously</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPI-2358</intervention_name>
    <description>Treatment on Days 1, 8 and 15 in a 28 day cycle</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Pathologically or histologically confirmed solid tumor malignancy&#xD;
&#xD;
          -  Patients must not be candidates for regimens known to provide clinical benefit.&#xD;
&#xD;
          -  All adverse events of any prior chemotherapy, surgery, or radiotherapy, must have&#xD;
             resolved to National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI CTCAE) (v. 3.0) Grade ≤ 2, except for neurological toxicity that must have&#xD;
             resolved to Grade ≤ 1.&#xD;
&#xD;
          -  Adequate bone marrow reserve, hepatic and renal function&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of chemotherapy, biological, immunotherapy or investigational agent&#xD;
             (therapeutic or diagnostic) within 21 days prior to receipt of study medication (6&#xD;
             weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major&#xD;
             surgery, other than diagnostic surgery, within 6 weeks before first study drug&#xD;
             administration. Radiotherapy within 4 weeks (some types of radiation therapy are&#xD;
             excluded regardless of interval since treatment).&#xD;
&#xD;
          -  Significant cardiac history or findings&#xD;
&#xD;
          -  Underlying conditions or medications associated with bleeding diathesis&#xD;
&#xD;
          -  Disorders associated with significant vascular pathology&#xD;
&#xD;
          -  Lung cancer with central chest tumors&#xD;
&#xD;
          -  Prior treatment with vascular disruptive agents&#xD;
&#xD;
          -  Seizure disorder requiring anticonvulsant therapy; prior transient ischemic attack or&#xD;
             cerebrovascular accident&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD) with hypoxemia&#xD;
&#xD;
          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C&#xD;
&#xD;
          -  Patients with a prior hypersensitivity reaction to any product containing Solutol&#xD;
             and/or propylene glycol&#xD;
&#xD;
          -  Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically&#xD;
             sterile or they must agree to use acceptable methods of birth control. Female patients&#xD;
             with childbearing potential must have a negative serum pregnancy test. Male patients&#xD;
             must be surgically sterile or agree to use an acceptable method of contraception.&#xD;
&#xD;
          -  Concurrent, active second malignancy for which the patient is receiving therapy,&#xD;
             excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew A Spear, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Nereus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute/Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245-3217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kristine C. Federico RN,BSN</name_title>
    <organization>Nereus Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

